Roemeling-van Rhijn Marieke, Khairoun Meriem, Korevaar Sander S, Lievers Ellen, Leuning Danielle G, Ijzermans Jan Nm, Betjes Michiel Gh, Genever Paul G, van Kooten Cees, de Fijter Hans Jw, Rabelink Ton J, Baan Carla C, Weimar Willem, Roelofs Helene, Hoogduijn Martin J, Reinders Marlies E
Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
Nephrology, Leiden University Medical Center, The Netherlands.
J Stem Cell Res Ther. 2013 Nov 25;Suppl 6(1):20780. doi: 10.4172/2157-7633.S6-001.
Recent studies with bone marrow (BM)-derived Mesenchymal Stromal Cells (MSC) in transplant recipients demonstrate that treatment with MSC is safe and clinically feasible. While BM is currently the preferred source of MSC, adipose tissue is emerging as an alternative. To develop efficient therapies, there is a need for preclinical efficacy studies in transplantation. We used a unique humanized transplantation model to study the immunosuppressive effect of human BM-MSC and adipose tissue-derived MSC (ASC).
Gene expression of BM-MSC and ASC and their capacity to inhibit activated PBMC proliferation was evaluated. The immunosuppressive effect of BM-MSC and ASC was studied in a humanized mouse model. SCID mice were transplanted with human skin grafts and injected with human allogeneic PBMC with or without administration of BM-MSC or ASC. The effect of MSC on skin graft rejection was studied by immunohistochemistry and PCR.
BM-MSC and ASC expressed TGFβ, CXCL-10 and IDO. IDO expression and acitivity increased significantly in BM-MSC and ASC upon IFN-γ stimulation. IFN-γ stimulated BM-MSC and ASC inhibited the proliferation of activated PBMC in a significant and dose dependent manner. In our humanized mouse model, alloreactivity was marked by pronounced CD45+ T-cell infiltrates consisting of CD4+ and CD8+ T cells and increased IFN-γ expression in the skin grafts which were all significantly inhibited by both BM-MSC and ASC.
BM-MSC and ASC are immunosuppressive and suppress alloreactivity in a preclinical humanized transplantation model.
近期针对移植受者的骨髓(BM)来源间充质基质细胞(MSC)的研究表明,MSC治疗是安全且具有临床可行性的。虽然目前BM是MSC的首选来源,但脂肪组织正逐渐成为一种替代来源。为了开发有效的治疗方法,需要进行移植前的临床前疗效研究。我们使用了一种独特的人源化移植模型来研究人BM-MSC和脂肪组织来源的MSC(ASC)的免疫抑制作用。
评估了BM-MSC和ASC的基因表达及其抑制活化外周血单个核细胞(PBMC)增殖的能力。在人源化小鼠模型中研究了BM-MSC和ASC的免疫抑制作用。将严重联合免疫缺陷(SCID)小鼠移植人皮肤移植物,并注射人同种异体PBMC,同时给予或不给予BM-MSC或ASC。通过免疫组织化学和聚合酶链反应(PCR)研究了MSC对皮肤移植物排斥反应的影响。
BM-MSC和ASC表达转化生长因子β(TGFβ)、CXC趋化因子配体10(CXCL-10)和吲哚胺2,3-双加氧酶(IDO)。在干扰素-γ(IFN-γ)刺激下,BM-MSC和ASC中的IDO表达及活性显著增加。IFN-γ刺激的BM-MSC和ASC以显著的剂量依赖性方式抑制活化PBMC的增殖。在我们的人源化小鼠模型中,同种异体反应性的特征是由CD4+和CD8+T细胞组成的明显的CD45+T细胞浸润以及皮肤移植物中IFN-γ表达增加,而这两者均被BM-MSC和ASC显著抑制。
在临床前的人源化移植模型中,BM-MSC和ASC具有免疫抑制作用并抑制同种异体反应性。